BP 897, a selective dopamine D3 receptor ligand with therapeutic potential for the treatment of cocaine-addiction - PubMed (original) (raw)
Review
BP 897, a selective dopamine D3 receptor ligand with therapeutic potential for the treatment of cocaine-addiction
F J Garcia-Ladona et al. CNS Drug Rev. 2003 Summer.
Abstract
BP 897 is a potent (K(i) = 0.92 nM) dopamine D(3) receptor compound developed for the treatment of cocaine abuse and craving. BP 897 has a high selectivity for the dopamine D(3) versus D(2) receptors (70-fold) and a moderate affinity for 5-HT(1A) receptors, (K(i) = 84 nM), adrenergic-alpha(1) (K(i) = 60 nM) and -alpha(2) adrenoceptors (K(i) = 83 nM). BP 897 displays significant intrinsic activity at the human dopamine D(3) receptor by decreasing forskolin-stimulated cAMP levels and by stimulating mitogenesis of dopamine D(3)-expressing NG108-15 cells. Although these findings suggest that BP 897 is a partial agonist, recent studies in Chinese Hamster Ovary (CHO) cells with expressed dopamine D(3) receptors demonstrated that BP 897 is devoid of any intrinsic activity but potently inhibits dopamine agonist effects (pIC(50) = 9.43 and 9.51) in agonist-induced acidification rate or increase of GTPgammaS binding, respectively. In addition, BP 897 inhibits in vivo (EC(50) = 1.1 mg/kg, i.v.) agonist-induced decrease of firing rate of dopaminergic neurons in the substantia nigra. It has been clearly shown that BP 897, 1 mg/kg, i.p., reduces cocaine-seeking behavior in rats, without producing reinforcement on its own. In rhesus monkeys, BP 897 is not self-administered (up to 30 microg/kg, i.v.) but reduces cocaine self-administration. The potential usefulness of BP 897 in the treatment of drug-seeking behavior is further supported by its effects in drug conditioning models. Although BP 897 reduces L-DOPA-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated monkeys, it provokes a return of parkinsonian symptoms. At high doses BP 897 has been reported to produce catalepsy in rats. Pharmacokinetic and toxicological data have not yet been published. These interesting preclinical findings with BP 897 provide additional validation for dopamine D(3) receptor as a therapeutic target for the treatment of cocaine abuse and its associated central nervous system (CNS) disorders. BP 897 recently entered phase II clinical studies.
Similar articles
- Effects of RGH-237 [N-{4-[4-(3-aminocarbonyl-phenyl)-piperazin-1-yl]-butyl}-4-bromo-benzamide], an orally active, selective dopamine D(3) receptor partial agonist in animal models of cocaine abuse.
Gyertyán I, Kiss B, Gál K, Laszlovszky I, Horváth A, Gémesi LI, Sághy K, Pásztor G, Zájer M, Kapás M, Csongor EA, Domány G, Tihanyi K, Szombathelyi Z. Gyertyán I, et al. J Pharmacol Exp Ther. 2007 Mar;320(3):1268-78. doi: 10.1124/jpet.106.107920. Epub 2006 Dec 14. J Pharmacol Exp Ther. 2007. PMID: 17170312 - Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors.
Campiani G, Butini S, Trotta F, Fattorusso C, Catalanotti B, Aiello F, Gemma S, Nacci V, Novellino E, Stark JA, Cagnotto A, Fumagalli E, Carnovali F, Cervo L, Mennini T. Campiani G, et al. J Med Chem. 2003 Aug 28;46(18):3822-39. doi: 10.1021/jm0211220. J Med Chem. 2003. PMID: 12930145 - Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist.
Pilla M, Perachon S, Sautel F, Garrido F, Mann A, Wermuth CG, Schwartz JC, Everitt BJ, Sokoloff P. Pilla M, et al. Nature. 1999 Jul 22;400(6742):371-5. doi: 10.1038/22560. Nature. 1999. PMID: 10432116 - BP-897 Bioprojet.
Preti A. Preti A. Curr Opin Investig Drugs. 2000 Sep;1(1):110-5. Curr Opin Investig Drugs. 2000. PMID: 11249586 Review. - [Pharmacology of antipsychotics at human dopamine D2 and D3 receptors].
Tadori Y, Kikuchi T. Tadori Y, et al. Nihon Shinkei Seishin Yakurigaku Zasshi. 2012 Feb;32(1):9-18. Nihon Shinkei Seishin Yakurigaku Zasshi. 2012. PMID: 22568121 Review. Japanese.
Cited by
- Neuronal Dopamine D3 Receptors: Translational Implications for Preclinical Research and CNS Disorders.
Kiss B, Laszlovszky I, Krámos B, Visegrády A, Bobok A, Lévay G, Lendvai B, Román V. Kiss B, et al. Biomolecules. 2021 Jan 14;11(1):104. doi: 10.3390/biom11010104. Biomolecules. 2021. PMID: 33466844 Free PMC article. Review. - New Drugs, Old Targets: Tweaking the Dopamine System to Treat Psychostimulant Use Disorders.
Newman AH, Ku T, Jordan CJ, Bonifazi A, Xi ZX. Newman AH, et al. Annu Rev Pharmacol Toxicol. 2021 Jan 6;61:609-628. doi: 10.1146/annurev-pharmtox-030220-124205. Annu Rev Pharmacol Toxicol. 2021. PMID: 33411583 Free PMC article. - (±)VK4-40, a novel dopamine D3 receptor partial agonist, attenuates cocaine reward and relapse in rodents.
Jordan CJ, He Y, Bi GH, You ZB, Cao J, Xi ZX, Newman AH. Jordan CJ, et al. Br J Pharmacol. 2020 Oct;177(20):4796-4807. doi: 10.1111/bph.15244. Epub 2020 Sep 17. Br J Pharmacol. 2020. PMID: 32851643 Free PMC article. - Dopamine D3 receptor-based medication development for the treatment of opioid use disorder: Rationale, progress, and challenges.
Galaj E, Newman AH, Xi ZX. Galaj E, et al. Neurosci Biobehav Rev. 2020 Jul;114:38-52. doi: 10.1016/j.neubiorev.2020.04.024. Epub 2020 May 3. Neurosci Biobehav Rev. 2020. PMID: 32376243 Free PMC article. Review. - Dopamine D3 receptor: A neglected participant in Parkinson Disease pathogenesis and treatment?
Yang P, Perlmutter JS, Benzinger TLS, Morris JC, Xu J. Yang P, et al. Ageing Res Rev. 2020 Jan;57:100994. doi: 10.1016/j.arr.2019.100994. Epub 2019 Nov 22. Ageing Res Rev. 2020. PMID: 31765822 Free PMC article. Review.
References
- Acri JB, Carter SR, Alling K, et al. Assessment of cocaine‐like discriminative stimulus effects of dopamine D3 receptor ligands. Eur J Pharmacol 1995;281:R7–R9. - PubMed
- Audinot V, Newman‐Tancredi A, Gobert A, et al. A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)‐S 14297, nafadotride, GR 103,691 and U 99194. J Pharmacol Exp Ther 1998;287:187–197. - PubMed
- Aujla H, Sokoloff P, Beninger RJ. A dopamine D3 receptor partial agonist blocks the expression of conditioned activity. Neuroreport 2002;13:173–176. - PubMed
- Aulakh CS, Wozniak KM, Haas M, Hill JL, Zohar J, Murphy DL. Food intake, neuroendocrine and temperature effects of 8‐OHDPAT in the rat. Eur J Pharmacol 1988;146:253–259. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical